SEC For	rm 4																	
	FORM	4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549												OMB APPROVAL			
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).			STAT		NT OF CHANGES IN BENEFICIAL OWNE						_	HIP	Estim	Estimated average burden		3235-0287 m 0.5		
transac contrac the pur securit to satis condition	chase or sale of	e pursuant to a r written plan for of equity r that is intended ve defense			01 36		OI UN	e investment (2 01 1940								
1. Name and Address of Reporting Person [*] Nickerson Joan					2. Issuer Name and Ticker or Trading Symbol <u>Verve Therapeutics, Inc.</u> [VERV]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
(Last) (First) (Middle) C/O VERVE THERAPEUTICS, INC. 201 BROOKLINE AVENUE, SUITE 601					3. Date of Earliest Transaction (Month/Day/Year) 01/08/2025							Officer (give title below) Other (specify below) Chief Administrative Officer						
(Street) BOSTON MA 02215					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line) ✓ Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City) (State) (Zip)						Persor												
1. Title of Security (Instr. 3) 2. Trans Date				2. Transac	action 2A. Deemed Execution Date			e, Transaction Disposed Code (Instr.		of, or Beneficiall ities Acquired (A) or d Of (D) (Instr. 3, 4 and		5. Amount of Securities Beneficially Owned Following		Form	: Direct Indirect	7. Nature of Indirect Beneficial Ownership		
							Code V	Amount	(A) o (D)	r Price	Reported Transacti (Instr. 3 a	on(s)			(Instr. 4)			
								uired, Dis s, options,				Owned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/)	Cod	saction e (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration D (Month/Day/	ate			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securitie Beneficia Owned Following Reported Transacti	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)		
				Cod	e V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)					
Stock Option (right to buy)	\$6.01	01/08/2025		Α		225,000		(1)	01/07/2035	Common Stock	225,000	\$0	225,000		D			
Restricted Stock Units	(2)	01/08/2025				40,000		(3)	(3)	Common Stock	40,000	\$0	40,000		D			
Explanatio	n of Respon	ses:																

1. The option was granted on January 8, 2025. 25% of the shares underlying the option will vest on January 8, 2026, and the remainder are scheduled to vest in equal monthly installments thereafter until January 8, 2029.

2. Each restricted stock unit represents a contingent right to receive one share of common stock.

3. On January 8, 2025, the reporting person was granted restricted stock units, vesting in three equal annual installments, beginning on April 1, 2026, and the remaining two installments vesting on April 1, 2027 and April 1, 2028.

/s/ Andrew Ashe, as Attorney-01/10/2025

in-Fact for Joan Nickerson

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.